The Administrative Core of the University of California, Irvine Alzheimer's Disease Research Center (UCI ADRC) provides innovative leadership, overall administrative support and oversight, and promotes the integration with the other cores, projects and pilot awards, thereby fostering the centeredness of our ADRC. The Administrative core establishes and implements policies to ensure the highest scientific and ethical studies, ensures compliance with HIPAA, NIH, and university policies and requirements related to human subjects, animal research, and stem cells. The Administrative Core oversees many critical areas to ensure the highest standards are achieved by providing administrative and financial supervision, development and promotion of scientific objectives, establishment and coordination of the External and Internal Advisory Committees, solicitation, review, and support for the pilot projects, interactions with the national ADC program, and recruitment, training and support of junior investigators and clinicians. A major function of the Administrative Core is to promote the ADRC with key leaders of the university administration and to procure resources. In short, the Administrative Core ensures that all operations of the UCI ADRC are functioning flawlessly and at the highest levels of productivity and standards.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016573-20
Application #
9686516
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Type
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92617
Torres, Maria D; Garcia, Octavio; Tang, Cindy et al. (2018) Dendritic spine pathology and thrombospondin-1 deficits in Down syndrome. Free Radic Biol Med 114:10-14
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Largent, Emily A; Karlawish, Jason; Grill, Joshua D (2018) Study partners: essential collaborators in discovering treatments for Alzheimer's disease. Alzheimers Res Ther 10:101
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Miranda, Andre M; Herman, Mathieu; Cheng, Rong et al. (2018) Excess Synaptojanin 1 Contributes to Place Cell Dysfunction and Memory Deficits in the Aging Hippocampus in Three Types of Alzheimer's Disease. Cell Rep 23:2967-2975
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Melikyan, Zarui A; Greenia, Dana E; Corrada, Maria M et al. (2018) Recruiting the Oldest-old for Clinical Research. Alzheimer Dis Assoc Disord :
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600

Showing the most recent 10 out of 518 publications